During the past decade, Inova Schar Cancer Institute conducted 94 clinical trials. In the 10-year time frame, 94 clinical trials started and 20 clinical trials were completed, i.e. on average, 21.3% percent of trials that started reached the finish line to date. In the past 5 years, 49 clinical trials started and 17 clinical trials were completed. i.e. 34.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Inova Schar Cancer Institute" #1 sponsor was "National Cancer Institute (NCI)" with 18 trials, followed by "Alliance for Clinical Trials in Oncology" with 10 trials sponsored, "Inova Health Care Services" with 6 trials sponsored, "Pfizer" with 6 trials sponsored and "ECOG-ACRIN Cancer Research Group" with 6 trials sponsored. Other sponsors include 55 different institutions and companies that sponsored additional 47 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Inova Schar Cancer Institute" #1 collaborator was "National Cancer Institute (NCI)" with 23 trials as a collaborator, "NRG Oncology" with 7 trials as a collaborator, "Genentech, Inc." with 4 trials as a collaborator, "Merck Sharp & Dohme LLC" with 4 trials as a collaborator and "Seagen Inc." with 4 trials as a collaborator. Other collaborators include 37 different institutions and companies that were collaborators in the rest 39 trials.

According to Clinical.Site data, the most researched conditions in "Inova Schar Cancer Institute" are "Breast Cancer" (7 trials), "Melanoma" (5 trials), "Breast Carcinoma" (3 trials), "Invasive Breast Carcinoma" (3 trials) and "Metastatic Breast Cancer" (3 trials). Many other conditions were trialed in "Inova Schar Cancer Institute" in a lesser frequency.

Most popular intervention types in "Inova Schar Cancer Institute" are "Drug" (81 trials), "Other" (43 trials), "Biological" (28 trials), "Radiation" (21 trials) and "Procedure" (19 trials). Other intervention types were less common.

The name of intervention was led by "Quality-of-Life Assessment" (21 trials), "Laboratory Biomarker Analysis" (16 trials), "Questionnaire Administration" (16 trials), "Pembrolizumab" (11 trials) and "Placebo" (11 trials). Other intervention names were less common.

The vast majority of trials in "Inova Schar Cancer Institute" are 90 trials for "All" genders, 9 trials for "Female" genders and 6 trials for "Male" genders.

Currently, there are NaN active trials in "Inova Schar Cancer Institute". undefined are not yet recruiting, 46 are recruiting, 31 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in Inova Schar Cancer Institute, 5 suspended trials, and 13 terminated clinical trials to date.

Out of the total trials that were conducted in Inova Schar Cancer Institute, 11 "Phase 1" clinical trials were conducted, 39 "Phase 2" clinical trials and 54 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 4 trials that are defined as “Not Applicable".